Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07685886 · ClinicalTrials.gov registry record · Phase 4
MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes
A Phase 4 study, sponsored by University of Colorado, Denver.
- Not yet
- Registry status
- Phase 4
- Development phase
- 110
- Enrollment target
NCT07685886 is a Phase 4 study that has not yet begun recruiting, run by University of Colorado, Denver. The registered enrollment target is 110 participants.
The verdict
NCT07685886, a Phase 4 study, has not yet begun recruiting, sponsored by University of Colorado, Denver.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 110 participants
- Enrollment target
Study Summary
Diabetes mellitus type 2 is associated with significant morbidity and mortality; and identifying new treatments for diabetes complications to be used alone or in combination with other therapies is a high priority. Hyperglycemia triggers proinflammatory pathways leading to damage in the kidneys, eyes and blood vessels; thus targeting proinflammatory lipid mediators called leukotrienes may represent a promising therapy for diabetes complications. This clinical trial seeks to investigate whether montelukast, a leukotriene antagonist, improves kidney, eye and vascular function in adult participants with type 2 diabetes and kidney disease.
Interventions
- DRUG Placebo
- DRUG Montelukast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2031-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07685886
The ClinicalTrials.gov registry entry for NCT07685886 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07685886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07685886 about?
NCT07685886 is a clinical study titled "MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes". Diabetes mellitus type 2 is associated with significant morbidity and mortality; and identifying new treatments for diabetes complications to be used alone or in combination with other therapies is a high priority. Hyperglycemia triggers proinflammatory pathways leading to damage in the kidneys, eye...
What is the current status of trial NCT07685886?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 110 participants. The study started on 2026-09-01. Estimated completion is 2031-08-31.
What interventions are being tested in trial NCT07685886?
The interventions under investigation include: Placebo (DRUG), Montelukast (DRUG).
Who is sponsoring clinical trial NCT07685886?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.